Incidence of cytopenias and severe cytopenias in the first 90 days following ide-cel
| Characteristic . | Apheresis N = 52 . | Day −5 N = 52 . | Day 0 N = 52 . | Day 7 N = 52 . | Day 14 N = 51 . | Day 21 N = 51 . | Day 30 N = 51 . | Day 90 N = 47 . |
|---|---|---|---|---|---|---|---|---|
| Leukopenia – n (%) | ||||||||
| Any grade | 32 (62%) | 23 (44%) | 51 (98%) | 50 (96%) | 42 (82%) | 47 (92%) | 42 (82%) | 26 (55%) |
| Grade ≥ 3 | 5 (10%) | 6 (12%) | 40 (77%) | 41 (79%) | 23 (45%) | 29 (57%) | 18 (35%) | 6 (13%) |
| Neutropenia – n (%) | ||||||||
| Any grade | 20 (38%) | 20 (38%) | 41 (79%) | 48 (92%) | 38 (75%) | 39 (76%) | 32 (63%) | 17 (36%) |
| Grade ≥ 3 | 2 (4%) | 5 (10%) | 28 (54%) | 42 (81%) | 26 (51%) | 26 (51%) | 20 (39%) | 5 (11%) |
| Anemia – n (%) | ||||||||
| Any grade | 44 (85%) | 46 (88%) | 48 (92%) | 50 (96%) | 47 (92%) | 44 (86%) | 46 (90%) | 33 (70%) |
| Grade ≥ 3 | 4 (8%) | 13 (25%) | 18 (35%) | 16 (31%) | 10 (20%) | 12 (24%) | 15 (29%) | 7 (15%) |
| Thrombocytopenia – n (%) | ||||||||
| Any grade | 32 (62%) | 30 (58%) | 41 (79%) | 48 (92%) | 42 (82%) | 48 (94%) | 46 (90%) | 31 (66%) |
| Grade ≥ 3 | 4 (8%) | 6 (12%) | 16 (31%) | 27 (52%) | 22 (43%) | 28 (55%) | 26 (51%) | 13 (28%) |
| Any cytopenia – n (%) | ||||||||
| Any grade | 48 (92%) | 48 (92%) | 52 (100%) | 51 (98%) | 51 (100%) | 50 (98%) | 50 (98%) | 41 (87%) |
| Grade ≥ 3 | 11 (21%) | 16 (31%) | 42 (81%) | 49 (94%) | 35 (69%) | 38 (75%) | 33 (65%) | 19 (40%) |
| Characteristic . | Apheresis N = 52 . | Day −5 N = 52 . | Day 0 N = 52 . | Day 7 N = 52 . | Day 14 N = 51 . | Day 21 N = 51 . | Day 30 N = 51 . | Day 90 N = 47 . |
|---|---|---|---|---|---|---|---|---|
| Leukopenia – n (%) | ||||||||
| Any grade | 32 (62%) | 23 (44%) | 51 (98%) | 50 (96%) | 42 (82%) | 47 (92%) | 42 (82%) | 26 (55%) |
| Grade ≥ 3 | 5 (10%) | 6 (12%) | 40 (77%) | 41 (79%) | 23 (45%) | 29 (57%) | 18 (35%) | 6 (13%) |
| Neutropenia – n (%) | ||||||||
| Any grade | 20 (38%) | 20 (38%) | 41 (79%) | 48 (92%) | 38 (75%) | 39 (76%) | 32 (63%) | 17 (36%) |
| Grade ≥ 3 | 2 (4%) | 5 (10%) | 28 (54%) | 42 (81%) | 26 (51%) | 26 (51%) | 20 (39%) | 5 (11%) |
| Anemia – n (%) | ||||||||
| Any grade | 44 (85%) | 46 (88%) | 48 (92%) | 50 (96%) | 47 (92%) | 44 (86%) | 46 (90%) | 33 (70%) |
| Grade ≥ 3 | 4 (8%) | 13 (25%) | 18 (35%) | 16 (31%) | 10 (20%) | 12 (24%) | 15 (29%) | 7 (15%) |
| Thrombocytopenia – n (%) | ||||||||
| Any grade | 32 (62%) | 30 (58%) | 41 (79%) | 48 (92%) | 42 (82%) | 48 (94%) | 46 (90%) | 31 (66%) |
| Grade ≥ 3 | 4 (8%) | 6 (12%) | 16 (31%) | 27 (52%) | 22 (43%) | 28 (55%) | 26 (51%) | 13 (28%) |
| Any cytopenia – n (%) | ||||||||
| Any grade | 48 (92%) | 48 (92%) | 52 (100%) | 51 (98%) | 51 (100%) | 50 (98%) | 50 (98%) | 41 (87%) |
| Grade ≥ 3 | 11 (21%) | 16 (31%) | 42 (81%) | 49 (94%) | 35 (69%) | 38 (75%) | 33 (65%) | 19 (40%) |
Numbers and percentage of patients with any grade and grade ≥ 3 leukopenia, neutropenia, anemia, thrombocytopenia, and any cytopenia from apheresis to day 90. Any grade cytopenias: Anemia with hemoglobin (Hb) < 11.4 g/dL; neutropenia with absolute neutrophil count (ANC) < 1800/μL; thrombocytopenia with platelets (Plt) < 143 000/μL. Grade 3 cytopenias: anemia with Hb < 8 g/dL; neutropenia with ANC < 1000/μL; thrombocytopenia with Plt < 50 000/μL. ide-cel, idecabtagene vicleucel.